Literature DB >> 24705491

A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII.

Scot A Fahs1, Matthew T Hille1, Qizhen Shi2, Hartmut Weiler3, Robert R Montgomery2.   

Abstract

The cellular source of coagulation factor VIII (FVIII) remains controversial. Like many coagulation proteins, FVIII is produced in the liver, and FVIII synthesis has long been associated with hepatocytes. But extrahepatic synthesis also occurs, and mounting evidence suggests that hepatocytes are not responsible for FVIII production. To determine the tissue that synthesizes FVIII, we developed a Cre/lox-dependent conditional knockout (KO) model in which exons 17 and 18 of the murine factor VIII gene (F8) are flanked by loxP sites, or floxed (F8(F)). In cells expressing Cre-recombinase, the floxed sequence is deleted, resulting in F8(F→KO) gene inactivation. When F8(F) mice were crossed with various tissue-specific Cre strains, we found that hepatocyte-specific F8-KO mice are indistinguishable from controls, whereas efficient endothelial-KO models display a severe hemophilic phenotype with no detectable plasma FVIII activity. A hematopoietic Cre model was more equivocal, so experimental bone marrow transplantation was used to examine hematopoietic FVIII synthesis. FVIII(null) mice that received bone marrow transplants from wild-type donors were still devoid of plasma FVIII activity after hematopoietic donor cell engraftment. Our results indicate that endothelial cells are the predominant, and possibly exclusive, source of plasma FVIII.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24705491      PMCID: PMC4055921          DOI: 10.1182/blood-2014-02-555151

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  51 in total

1.  Allogeneic bone marrow transplantation in a child with severe aplastic anemia and hemophilia A.

Authors:  M Ostronoff; F Ostronoff; G Campos; S Arruda; C Vaz; R Florencio; R Calixto; A P Souto Maior; A Sucupira; M Domingues; C Tagliari
Journal:  Bone Marrow Transplant       Date:  2006-03       Impact factor: 5.483

2.  Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase.

Authors:  C Postic; M Shiota; K D Niswender; T L Jetton; Y Chen; J M Moates; K D Shelton; J Lindner; A D Cherrington; M A Magnuson
Journal:  J Biol Chem       Date:  1999-01-01       Impact factor: 5.157

3.  Expression of factor VIII by murine liver sinusoidal endothelial cells.

Authors:  H Do; J F Healey; E K Waller; P Lollar
Journal:  J Biol Chem       Date:  1999-07-09       Impact factor: 5.157

4.  Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies.

Authors:  L Bi; R Sarkar; T Naas; A M Lawler; J Pain; S L Shumaker; V Bedian; H H Kazazian
Journal:  Blood       Date:  1996-11-01       Impact factor: 22.113

5.  cis-acting elements and transcription factors involved in the promoter activity of the human factor VIII gene.

Authors:  M S Figueiredo; G G Brownlee
Journal:  J Biol Chem       Date:  1995-05-19       Impact factor: 5.157

6.  Lack of desmopressin (DDAVP) response in men with hemophilia A following liver transplantation.

Authors:  P A Lamont; M V Ragni
Journal:  J Thromb Haemost       Date:  2005-10       Impact factor: 5.824

7.  VE-Cadherin-Cre-recombinase transgenic mouse: a tool for lineage analysis and gene deletion in endothelial cells.

Authors:  Jackelyn A Alva; Ann C Zovein; Arnaud Monvoisin; Thomas Murphy; Anthony Salazar; Natasha L Harvey; Peter Carmeliet; M Luisa Iruela-Arispe
Journal:  Dev Dyn       Date:  2006-03       Impact factor: 3.780

8.  Assessing the role of hematopoietic plasticity for endothelial and hepatocyte development by non-invasive lineage tracing.

Authors:  Matthias Stadtfeld; Thomas Graf
Journal:  Development       Date:  2004-12-02       Impact factor: 6.868

9.  Transplantation of endothelial cells corrects the phenotype in hemophilia A mice.

Authors:  V Kumaran; D Benten; A Follenzi; B Joseph; R Sarkar; S Gupta
Journal:  J Thromb Haemost       Date:  2005-09       Impact factor: 5.824

10.  Transplantation of spleen cells in patients with hemophilia A. A report of 20 cases.

Authors:  L Liu; S Xia; J Seifert
Journal:  Transpl Int       Date:  1994-05       Impact factor: 3.782

View more
  66 in total

1.  Analysis of MCFD2- and LMAN1-deficient mice demonstrates distinct functions in vivo.

Authors:  Min Zhu; Chunlei Zheng; Wei Wei; Lesley Everett; David Ginsburg; Bin Zhang
Journal:  Blood Adv       Date:  2018-05-08

2.  Evaluation of high-fat high-fructose diet treatment in factor VIII (coagulation factor)-deficient mouse model.

Authors:  Alaknanda Mishra; Shailendra Arindkar; Preeti Sahay; Jerald Mahesh Kumar; Pramod K Upadhyay; Subeer S Majumdar; Perumal Nagarajan
Journal:  Int J Exp Pathol       Date:  2018-04-15       Impact factor: 1.925

3.  Endothelial cells derived from patients' induced pluripotent stem cells for sustained factor VIII delivery and the treatment of hemophilia A.

Authors:  Melanie Rose; Kewa Gao; Elizabeth Cortez-Toledo; Emmanuel Agu; Alicia A Hyllen; Kelsey Conroy; Guangjin Pan; Jan A Nolta; Aijun Wang; Ping Zhou
Journal:  Stem Cells Transl Med       Date:  2020-03-12       Impact factor: 6.940

4.  The endothelial lectin clearance receptor CLEC4M binds and internalizes factor VIII in a VWF-dependent and independent manner.

Authors:  Laura L Swystun; Colleen Notley; Ilinca Georgescu; Jesse D Lai; Kate Nesbitt; Paula D James; David Lillicrap
Journal:  J Thromb Haemost       Date:  2019-03-19       Impact factor: 5.824

5.  The search for the origin of factor VIII synthesis and its impact on therapeutic strategies for hemophilia A.

Authors:  Valder R Arruda
Journal:  Haematologica       Date:  2015-07       Impact factor: 9.941

6.  Hemostatic Factors, APOL1, and ESRD Risk: Another Piece of the Puzzle?

Authors:  Walter G Wasser; Etty Kruzel-Davila
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-17       Impact factor: 8.237

7.  Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models.

Authors:  Joshua I Siner; Benjamin J Samelson-Jones; Julie M Crudele; Robert A French; Benjamin J Lee; Shanzhen Zhou; Elizabeth Merricks; Robin Raymer; Timothy C Nichols; Rodney M Camire; Valder R Arruda
Journal:  JCI Insight       Date:  2016-10-06

8.  Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice.

Authors:  C K Baumgartner; J G Mattson; H Weiler; Q Shi; R R Montgomery
Journal:  J Thromb Haemost       Date:  2016-11-08       Impact factor: 5.824

Review 9.  Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.

Authors:  Steven W Pipe; Robert R Montgomery; Kathleen P Pratt; Peter J Lenting; David Lillicrap
Journal:  Blood       Date:  2016-09-01       Impact factor: 22.113

10.  Complexity and diversity of F8 genetic variations in the 1000 genomes.

Authors:  J N Li; I G Carrero; J F Dong; F L Yu
Journal:  J Thromb Haemost       Date:  2015-10-20       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.